Ionis Pharmaceuticals has reached a significant milestone with the FDA’s approval of Zanvastro, a groundbreaking antisense oligonucleotide therapy. This marks Ionis’ inaugural independent launch in the neurology sector, setting the stage for further advancements in treating rare neurodegenerative disorders, including Angelman syndrome.
A Historic Approval
Zanvastro, previously known as zilganersen, has become the first-ever disease-modifying treatment for Alexander disease, an ultrarare genetic disorder. The FDA granted this approval ahead of its scheduled PDUFA date of September 22, highlighting its urgency and importance. This therapy directly targets the harmful protein accumulation that characterizes Alexander disease, providing hope for patients and their families.
Emily Freilich, director of the FDA’s Division of Neurology I, remarked on the approval as a “landmark moment” for the Alexander disease community, emphasizing the absence of previous treatment options beyond supportive care.
Understanding Alexander Disease
Alexander disease is an extremely rare leukodystrophy, impacting approximately one in 3 million individuals globally. It arises from mutations in the GFAP gene, leading to an overproduction of the GFAP protein, which becomes toxic within glial cells in the central nervous system. Over time, this toxicity disrupts neuronal function and myelin integrity, culminating in various symptoms such as motor and cognitive impairments, loss of independence, and difficulties with essential motor functions. The disease can present itself in childhood or later in life.
In cases of early onset, children initially develop typically before exhibiting troubling symptoms that progressively lead to severe decline, often resulting in fatal outcomes. Holly Kordasiewicz, head of Development at Ionis, described the disease as particularly challenging, given its rapid progression and devastating effects.
Mechanism of Action
Zanvastro employs an innovative approach by binding to RNA, thereby reducing the production of the deleterious GFAP protein. Amy Waldman, a pediatric neurologist at Children’s Hospital of Philadelphia and medical director of the Leukodystrophy Center, explained that this mechanism is central to the therapy’s intended effects.
In clinical trials, Zanvastro demonstrated promising results. The pivotal Phase 3 trial involved 49 patients aged five and older, who received a 50-mg dose of the therapy. Participants exhibited statistically significant stabilization in their gait speed, as measured by the 10-meter walk test. This outcome signifies a noteworthy achievement in managing a degenerative disease, as Kordasiewicz pointed out that maintaining stability in such conditions is a remarkable feat.
Positive Outcomes in Pediatric Patients
A separate open-label substudy focused on younger patients under two years old, where traditional measures of walking speed were deemed unreliable. Instead, a comprehensive assessment of various motor skills was utilized. Encouragingly, children treated with Zanvastro showed improvements, while those in the control group experienced declines.
Kordasiewicz expressed excitement over these findings, noting that the therapy allows for some neurodevelopment in younger patients, a crucial aspect of their overall growth and capabilities.
Realistic Expectations for Stability
Despite the positive trial results, Waldman maintained a cautious perspective. In the context of rare leukodystrophies like Alexander disease, achieving stability is the primary goal. Families understandably aspire for improvement and healing, yet the focus remains on slowing disease progression rather than reversing permanent neurological damage.
Ionis’ Expanding Portfolio
Zanvastro represents Ionis’ second independent launch in a year following the approval of Tryngolza for severe hypertriglyceridemia. This success reflects Ionis’ commitment to advancing RNA-targeted therapies in neurology. The company has cultivated a rich history in the field, notably with the approval of Spinraza for spinal muscular atrophy and Qalsody for amyotrophic lateral sclerosis.
Kordasiewicz highlighted the strategic importance of launching Zanvastro, stating that it establishes a presence in the neurology community while positioning Ionis for future independent approvals, including a therapy for Angelman syndrome.
Future Directions
Ionis is currently conducting the Phase 3 REVEAL study for obudanersen, another RNA-based therapy aimed at treating Angelman syndrome. This condition, characterized by neurodegeneration, presents unique challenges for targeted therapies. Following Ultragenyx’s disappointing results with their ASO, Ionis remains optimistic about obudanersen’s potential based on encouraging early trial results.
The REVEAL study is anticipated to yield results by August 2027, paving the way for more advancements in the treatment of neurodegenerative diseases.
Conclusion
The approval of Zanvastro for Alexander disease is a remarkable achievement for Ionis Pharmaceuticals and the patients it serves. As the company prepares for future launches, the implications of this therapy extend beyond just Alexander disease, signaling a broader commitment to addressing rare neurological disorders. The journey ahead is filled with promise, and the Alexander disease community now has a reason to celebrate a significant victory in the world of biotech.
Key Takeaways:
- Zanvastro is the first disease-modifying treatment for Alexander disease.
- The therapy targets GFAP protein accumulation, a hallmark of the condition.
- Clinical trials showed significant stabilization of motor function in patients.
- Ionis is poised for further developments in neurology, including Angelman syndrome.
- The focus remains on achieving stability rather than reversing neurological damage.
Read more → www.biospace.com